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Background: Aminophylline, an established bronchodilator, is also purported to be an
effective diuretic and anti-inflammatory agent. However, the data to support these con-
tentions are scant. We conducted a prospective, open-label, single arm, single center
study to assess the hypothesis that aminophylline increases urine output and decreases
inflammation in critically ill children.
Methods: Children less than 18 years of age admitted to the pediatric intensive care unit
who were prescribed aminophylline over a 24-h period were eligible for study. The use
and dosing of aminophylline was independent of the study and was at the discretion of
the clinical team. Data analyzed consisted of demographics, diagnoses, medications, and
markers of pulmonary function, renal function, and inflammation. Data were collected at
baseline and at 24-h after aminophylline initiation with primary outcomes of change in urine
output and inflammatory cytokine concentrations.
Results:Thirty-five patients were studied. Urine output increased significantly with amino-
phylline use [median increase 0.5 mL/kg/h (IQR: −0.3, 1.3), p=0.05] while blood urea
nitrogen and creatinine concentrations remained unchanged. Among patients with elevated
C-reactive protein concentrations, levels of both interleukin-6 (IL-6) and IL-10 decreased at
24 h of aminophylline therapy. There were no significant differences in pulmonary compli-
ance or resistance among patients invasively ventilated at both time points. Side effects
of aminophylline were detected in 7 of 35 patients.
Conclusion: Although no definitive conclusions can be drawn from this study, amino-
phylline may be a useful diuretic and effective anti-inflammatory medication in critically
ill children. Given the incidence of side effects, the small sample size and the uncontrolled
study design, further study is needed to inform the appropriate use of aminophylline in
these children.
Keywords: aminophylline, respiratory function, inflammation, pediatrics, phosphodiesterase inhibition, adenosine
receptor blockade, acute kidney injury
INTRODUCTION
Aminophylline, the ethylenediamine salt of theophylline, is a
well-established medication that promotes bronchodilatation by
increasing the tissue concentrations of cyclic adenine monophos-
phate (cAMP) via phosphodiesterase inhibition (1). This phar-
macological effect enables it to be useful in the treatment of a
number of respiratory conditions including asthma (2). Despite
this well documented efficacy, the advent of other bronchodilators
that are effective, less prone to toxicity, and easier to adminis-
ter and monitor has resulted in a dramatic decline in its use for
reactive airway disease. However, in addition to its impact on air
flow, aminophylline has been demonstrated to have other effects
that may be beneficial to the critically ill child. It has been found
in a variety of settings to be a useful diuretic and renoprotective
agent (3–12). Moreover, various laboratory, animal, and small clin-
ical studies have reported potent anti-inflammatory properties of
aminophylline (13–19).
Given these potential renal and anti-inflammatory benefits,
and its well-established benefit on bronchoconstriction, amino-
phylline may benefit a number of critically ill children with a
variety of conditions. However, the data to support the use of
aminophylline in this patient population is not well established.
We undertook a prospective, open-label, and single arm study of
the physiologic effects of aminophylline in a tertiary care pediatric
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intensive care unit (PICU). We hypothesized that aminophylline
use would augment urine output and decrease inflammation in
critically ill children.
MATERIALS AND METHODS
All patients less than 18 years of age admitted to the PICU who were
prescribed aminophylline were screened for inclusion. Patients
were excluded if they weighed less than 2.3 kg or if their initial
hemoglobin concentration was less than 8 g/dL to minimize the
risk associated with the extra blood draw required for the study.
The Institutional Review Board of the Pennsylvania State Uni-
versity College of Medicine approved the protocol and informed
consent was obtained for all patients enrolled.
The use and dosing of aminophylline was independent of
the study and was at the discretion of the clinical team. In
our PICU, aminophylline administration is protocolized using
an intermittent dosing regimen with a goal theophylline trough
of 4–8µg/mL (Figure 1). Trough concentrations are assessed
every 24 h. When administered as a continuous infusion, pri-
marily for severe bronchospasm (e.g., status asthmaticus), target
theophylline concentrations are 10–20µg/mL.
Data were collected at baseline prior to the administration of
aminophylline, and then again, 24 h after the initiation of therapy.
Collected data consisted of demographics, diagnoses, medications,
and vital signs. In addition, data were obtained to assess the
impact of aminophylline on renal function, inflammation, and
pulmonary function as described below.
RENAL FUNCTION
Data collected for the assessment of renal function consisted of
serum blood urea nitrogen (BUN) and creatinine concentrations,
FIGURE 1 | Aminophylline dosing guidelines. The figure depicts the
standard intermittent dosing regimen used at the study center. This dosing
regimen is based on institution-specific clinical experience. The goal trough
theophylline concentration is 4–8µg/mL. This trough concentration is
assessed after four maintenance doses have been administered.
diuretic use, and urine output. For the baseline determination of
urine output, the previous 24 h prior to aminophylline admin-
istration was used. If urine was not collected for an entire 24 h
prior to the aminophylline administration, the urine output for
the entire time period prior to aminophylline administration was
determined and standardized in terms of milliliters per kilogram
per hour. Urine output was also determined by age group to assess
if a relationship existed between aminophylline effect and age.
ANTI-INFLAMMATORY EFFECTS
Data collected for the assessment of inflammation consisted of
white blood cell counts, C-reactive protein (CRP) concentrations,
glucose concentrations, and anti-inflammatory medication use.
Those patients with elevated CRP concentrations, defined a priori
as values greater than 1.5 mg/dL at baseline, underwent measure-
ments of interleukin-6 (IL-6), IL-8, IL-10, and tumor necrosis
factor alpha (TNF-alpha). These samples, drawn at baseline (at the
same time as the CRP level) and at 24-h, were immediately cen-
trifuged for 10 min. After separation, the plasma was then stored at
−70° centigrade. Cytokine analysis was performed on only those
samples from patients found to have a CRP concentration greater
than 1.5 mg/dL and it was performed utilizing multi-analyte pro-
filing (MAP) technology (Myriad RBM, Inc., Austin, TX, USA).
Although 90 different cytokine analyses were performed, it was
decided a priori that only the four cytokines listed would be
assessed in this study.
PULMONARY FUNCTION
Data collected relevant to the assessment of pulmonary function
included blood gas results, pulse oximeter recordings, and ventila-
tor settings. Additionally, airway resistance and compliance (both
static and dynamic) were determined for intubated patients using
the assessment tools of the Servo-I ventilator (Maquet Critical
Care, Rastatt, Germany) with the patient sedated and not actively
breathing over the ventilator.
STATISTICAL ANALYSIS
Descriptive statistics were performed for all variables; means, stan-
dard errors of the mean, medians, and interquartile ranges (IQR).
There were two primary outcomes of interest; the effect of amino-
phylline on urine output and on concentrations of inflammatory
cytokines with its impact on pulmonary function being a sec-
ondary outcome of interest. Consequently, a Wilcoxon Signed
Rank test was performed to compare 24-h after aminophylline
therapy values to baseline. To account for potential confounding
effects of concomitant medications, total dosages were quantitated
and four of the authors (Steven E. Lucking, Gary D. Ceneviva,
Neal J. Thomas, Robert F. Tamburro) reviewed all medications
and independently determined if there was an increase, a decrease,
or no change in the dosing of other diuretics (for renal analysis)
and anti-inflammatory medications (for inflammation analysis)
across the two time points of the study. The authors were blinded
to all outcomes of interest at the time of these determinations. If
the authors were not in concordance, the case was discussed until
all differences were resolved. A subset analysis was performed on
only those patients who received the same or less of these other
medications for their respective assessments. An alpha value of
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FIGURE 2 | Patients enrolled and assessed in various components of the study. The figure depicts the total enrollment of patients into the trial and the
number that underwent the various components of analysis.
0.05 defined statistical significance. Statistical analyses were per-
formed using version 9 of the SAS statistical software program
(SAS Institute, Inc., Cary, NC, USA).
RESULTS
Thirty-six patients were enrolled; 35 were available for analysis
because one patient died within hours of enrollment (Figure 2).
Ages ranged from 1 week to 18 years. The most common diagnoses
included bronchiolitis (n= 9), cardiac disease (n= 6), and sepsis
(n= 6) (Table 1).
RENAL FUNCTION
Thirty-four patients had pre- and post-aminophylline urine out-
put assessed; one patient was excluded from this analysis because
of concomitant diabetes insipidus. Among these 34 patients, the
urine output increased from a median of 3.5 [IQR: 2.0, 5.0] at
baseline to 4.2 [IQR: 2.7, 5.6] at 24-h with a median increase of
1.0 mL/kg/h ([IQR: −0.1, 1.5], p= 0.0004) (Table 2). The BUN
concentrations remained unchanged between baseline and 24-h
(median increase 1.0 mg/dL [IQR: 0.0, 4.0], p= 0.16). There was
also no change in the creatinine concentrations (median increase
0.02 mg/dL [IQR:−0.07, 0.07], p= 0.99) (Table 2).
Thirty-one patients received concomitant diuretics during the
study period. Ten patients received increased diuretic therapy
during the 24 h of aminophylline therapy. Consequently, urine
output was assessed among the 24 patients that received the same
or less concomitant diuretics during the 24 h after the start of
aminophylline as during the previous 24 h. Within this subset,
the urine output significantly increased with a median increase
of 0.5 mL/kg/h per patient ([IQR: −0.3, 1.3], p= 0.05) (Table 2).
Fifteen of these 24 patients (63%) experienced an increased urine
output with aminophylline use. There was no change in BUN con-
centrations among this cohort (median increase 1.0 [IQR: 0.0, 4.0],
p= 0.15) nor in creatinine values (median decrease 0.03 [IQR:
−0.08, 0.05], p= 0.30) (Table 2).
In an attempt to determine if there was an effect of age on
response to aminophylline, urine output was assessed by age group
among the 24 patients that received the same or less concomitant
diuretics during the 24 h after the start of aminophylline. Although
the numbers are small in each age group, aminophylline appeared
to be more effective in the children less than 10 years of age as
compared to those over 10 years of age (Figure 3, median change
in urine output 1.0 [IQR:−0.1, 1.5] versus−0.2 [IQR:−0.7, 0.1],
respectively, p= 0.05).
ANTI-INFLAMMATORY EFFECTS
There was no change in white blood cell count or glucose con-
centration between the two time points and comparable results
were obtained for these parameters for both the entire cohort and
for the subset with elevated CRP concentrations (Table 3). Nine-
teen patients had CRP concentrations greater than 1.5 mg/dL and
underwent cytokine analysis. For these patients, baseline CRP val-
ues ranged from 1.7 to >27 mg/dL (median 9.0 [IQR: 4.1, 24.3].
The median decrease in IL-6 concentrations between baseline and
24 h was 17.6 pg/mL [IQR: −5.1, −43.7], p< 0.0001) (Table 3).
Excluding the three patients who had an increase in their steroid
or other anti-inflammatory medications during the 24 h after
the start of aminophylline, yielded comparable results (median
decrease 19.0 [IQR:−8.6,−57.7], p< 0.0001) (Table 3). Baseline
IL-10 concentrations also differed from 24-h concentrations; the
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Table 1 | Baseline data of entire study cohort.
Variables
AGE (MONTHS)
Mean 51.5±11.5
Median 14.8 [IQR: 1.6, 102.5]
GENDER
Males 23 (66%)
Females 12 (34%)
RACE/ETHNICITY
White 23 (66%)
Hispanic 10 (29%)
African American 2 (6%)
PRIMARY DIAGNOSIS
Bronchiolitis 9 (26%)
Cardiac disease 6 (17%)
Sepsis 6 (17%)
Pneumonia 4 (11%)
Bronchopulmonary dysplasia 3 (9%)
Near drowning 2 (6%)
Neuromuscular disease 2 (6%)
Tracheal ring 1 (3%)
Thoracic mass 1 (3%)
Status asthmaticus 1 (3%)
CHEST RADIOGRAPHS
Bilateral disease 27 (77%)
Unilateral disease 3 (9%)
Clear 5 (14%)
BASELINE RESPIRATORY SUPPORT
Invasive ventilation 28 (80%)
BiLevel Positive Airway Pressure (BiPAP) 3 (9%)
Nasal cannula 2 (6%)
High flow nasal cannula (VapoTherm®) 1 (3%)
Face mask 1 (3%)
median decrease in IL-10 concentrations was 15.0 ([IQR: −3.0,
−33.0], p= 0.001) (Table 3). When the three patients who had an
increase in their anti-inflammatory medications during the 24 h
after aminophylline initiation were excluded, the median decrease
in IL-10 concentrations of 12.0 (IQR: −2.5, −41.0) was compa-
rable to the entire cohort and remained statistically significant
(p= 0.009) (Table 3). Baseline IL-8 concentrations also differed
from 24-h concentrations; (median decrease 14.0 [IQR: −2.0,
−36.0], p= 0.05) (Table 3). However, when the three patients who
had an increase in their concomitant anti-inflammatory medica-
tions were excluded, the median decrease in IL-8 concentrations
of 13.2 (IQR: −2.2, −41.2) only trended toward significance
(p= 0.09) (Table 3). TNF-alpha concentrations did not change
over the 24 h study period (Table 3).
PULMONARY FUNCTION
Twenty-eight patients received invasive mechanical ventilation at
baseline; three others required non-invasive bilateral positive air-
way pressure. Twenty-seven (77%) patients had bilateral lung
involvement based on their chest radiograph (Table 1).
Twenty-four patients were invasively ventilated at both time
points (prior to aminophylline and at 24-h after the start of
aminophylline) and underwent assessment of respiratory func-
tion. Among this group, there were no statistically significant
differences in static compliance (median change 0.40 mL/cm H2O
[IQR:−0.45, 0.80], p= 0.33) or airway resistance (median change
0.5 cm H2O/L/s [IQR: −35.5, 4.5], p= 0.29) between the two
time points (Table 4). There was an increase in dynamic compli-
ance that approached statistical significance (median change 0.40
[IQR: 0.0, 0.60], p= 0.08).
DRUG CONCENTRATIONS AND SIDE EFFECTS
Aminophylline was administered as a continuous infusion in 3 of
the 35 (9%) patients; the others received it via intermittent dosing.
Among the three patients who received aminophylline as a contin-
uous infusion, the 24-h serum theophylline concentrations were
10.5, 12.1, and 13.9µg/mL. The median 24-h serum trough theo-
phylline concentration for the patients who received intermittent
dosing was 3.7 with a range of 1.1–9.4µg/mL [IQR: 2.8, 5.8].
Side effects were identified in 7 of the 35 patients (20%) (all
receiving intermittent dosing) during their intensive care course,
primarily occurring after the defined study period (i.e., after the
initial 24 h of aminophylline therapy) (Table 5). All patients com-
pleted at least 24 h of therapy. Aminophylline was ultimately
discontinued in the seven patients; again, none within the first
24 h of therapy, but three within the first 48 h. Identified side
effects included agitation, increased nasogastric output, cardiac
ectopy, and tachydysrhythmias (Table 5). Four patients developed
dysrhythmias including supraventricular tachycardia, ventricular
tachycardia, and pre-mature atrial contractions. Given the criti-
cal condition of these children, other explanations existed for the
dysrhythmias. Despite the occurrence of these tachydysrhythmias,
the baseline median heart rate for the entire cohort was 138 beats
per minute [IQR: 127, 151] and remained essentially unchanged
at 24 h (median 141 [IQR: 126, 154], p= 0.74).
DISCUSSION
In this prospective, open-label, single arm, single center study, the
use of aminophylline in critically ill children appeared to be asso-
ciated with an increase in urine output and a decrease in cytokines
of paramount importance to the inflammatory process.
The use of aminophylline for renal protection from acute kid-
ney injury (AKI) is not novel. The efficacy of aminophylline for
renal protection has been reported in cisplatin- (3), tacrolimus-
(4), and contrast-induced (5, 6) AKI, in animal models of kidney
transplantation (20), and in the vasomotor nephropathy of very
pre-term newborns (21). However, its use in critically ill infants
and children is not well described. Bell reported a small case
series of 10 critically ill children who had a significant increase
in urine output with theophylline administration (7). However,
in that report, there was no report of BUN or creatinine con-
centrations, and the concomitant use of low dose dopamine con-
founded the interpretation and the general applicability of the
results. In another small retrospective case series, the administra-
tion of aminophylline to five neonates appeared to be associated
with an increase in urine output; however, the lack of a blad-
der catheter complicated interpretation of the study results (8).
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Table 2 | Assessment of renal variables before and after 24 h of aminophylline.
Variable Baseline value 24-h value pValue
ENTIRE COHORT (n=34)
Urine outputa 3.6±0.4 (3.5 [2.0, 5.0]) 4.7±0.5 (4.2 [2.7, 5.6]) 0.0004
BUNb 20.7±3.1 (13.5 [8.0, 27.0]) 22.5±3.9 (15.0 [9.0, 25.0]) 0.16
Creatinineb 0.70±0.15 (0.38 [0.27, 0.55]) 0.75±0.19 (0.34 [0.30, 0.55]) 0.99
SUBSET THAT RECEIVEDTHE SAME OR LESS CONCOMITANT DIURETICS DURING THE 24 h AFTER THE START OF AMINOPHYLLINE (n=24)
Urine outputa 3.6±0.5 (3.4 [1.9, 5.1]) 4.4±0.6 (3.5 [2.3, 5.5]) 0.05
BUNb 24.0±4.0 (14.5 [10.5, 33.5]) 26.7±5.1 (15.0 [10.0, 28.0]) 0.15
Creatinineb 0.75±0.18 (0.41 [0.32, 0.69]) 0.81±0.24 (0.37 [0.31, 0.66]) 0.30
Both the mean plus/minus the standard error of the mean as well as the median (in parentheses) with the corresponding interquartile range [in brackets] are displayed
for each value at each time point.
The p value was determined by the difference of the two values for each patient using the Wilcoxon Signed Rank test and was based on only the patients who had
values recorded at both time points.
aUrine output is reported in terms of milliliters per kilogram per hour.
bThe units for BUN and creatinine are milligrams per deciliter.
FIGURE 3 |The change in urine output (milliliters per kilogram per
hour) over the 24 h of aminophylline therapy by age group. The
figure illustrates the change in urine output (milliliters per kilogram per
hour) over the 24 h of aminophylline therapy by age group. The change
in urine output (milliliters per kilogram per hour) over the 24 h of
aminophylline therapy is plotted along the y -axis. The x -axis contains
the four age groups divided in approximately equal groups. The number
of study patients assessed in age group is depicted by the “n=” within
the parentheses. The center line within the “box” reflects the median
while the ends of the “box” reflect the 25th and 75th percentile,
respectively. The “whiskers” extending from the box reflect the entire
range of values.
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Table 3 | Assessment of inflammatory parameters before and after 24 h of aminophylline.
Variable Baseline value 24-h value pValue
SUBSET THAT HAD AN ELEVATED C-REACTIVE PROTEIN AT BASELINE (n=19)
White blood cella 11.4±2.0 (9.4 [7.5, 11.2]) 10.9±1.6 (10.0 [6.5, 12.8]) 0.76
Glucoseb 125.6±8.7 (119 [97, 145]) 127.7±7.9 (121 [106, 143]) 0.99
IL-6c 156.1±89.7 (27.0 [9.4, 172.0]) 37.3±13.9 (9.4 [4.3, 20.0]) <0.0001
IL-8c 199.7±69.3 (89 [51, 141]) 202.7±98.1 (64 [34, 99]) 0.05
IL-10c 211.5±113.1 (40.0 [20.0, 58.0]) 72.9±34.6 (21.0 [14.0, 33.0]) 0.001
TNF-alphac 15.4±3.1 (12.0 [7.5, 17.0]) 11.0±1.6 (8.5 [6.8, 12.0]) 0.26
SUBSET OF ABOVE COHORT THAT RECEIVED THE SAME OR LESS CONCOMITANT ANTI-INFLAMMATORY MEDICATIONS DURING THE 24 h
AFTER THE START OF AMINOPHYLLINE (n=16)
IL-6c 180.2±105.9 (27.0 [12.7, 183.0]) 42.4±16.3 (7.6 [4.3, 56.5]) <0.0001
IL-8c 218.7±81.7 (85.5 [49.5, 164.0]) 225.4±116.1 (61.0 [33.5, 157.0]) 0.09
IL-10c 106.1±53.5 (33.0 [16.5, 48.5]) 78.7±41.0 (17.0 [13.5, 30.0]) 0.009
TNF-alphac 12.8±2.5 (10.5 [6.8, 14.0]) 10.8±1.9 (8.0 [6.5, 12.0]) 0.26
Both the mean plus/minus the standard error of the mean as well as the median (in parentheses) with the corresponding interquartile range [in brackets] are displayed
for each value at each time point.
The p value was determined by the difference of the two values for each patient using the Wilcoxon Signed Rank test and was based on only the patients who had
values recorded at both time points.
aWhite blood cell count expressed in terms of 1000 cells/µL.
bBlood glucose levels expressed in units of milligrams per deciliter.
cCytokine levels expressed in units of picograms per milliliter.
Table 4 | Assessment of pulmonary variables before and after 24 h of aminophylline.
Entire cohort intubated and ventilated at both time points (n=24)
Variable Baseline value 24-h value pValue
Static compliancea 9.5±2.1 (4.4 [2.8, 14.6]) 12.4±3.0 (5.3 [3.0, 16.4]) 0.33
Dynamic compliancea 8.6±1.9 (3.7 [2.3, 14.7]) 11.3±3.0 (4.0 [2.3, 18.4]) 0.08
Resistanceb 106.1±13.8 (100 [34, 137]) 102.3±19.5 (79 [34, 142]) 0.29
pH 7.42±0.01 (7.43 [7.39, 7.47]) 7.46±0.01 (7.46 [7.42, 7.49]) 0.002
SF ratioc 240±14 (232.5 [190, 325]) 248±15 (245 [194, 323.3]) 0.17
Both the mean plus/minus the standard error of the mean as well as the median (in parentheses) with the corresponding interquartile range [in brackets] are displayed
for each value at each time point.
The p value was determined by the difference of the two values for each patient using the Wilcoxon Signed Rank test and was based on only the patients who had
values recorded at both time points.
aThe units for compliance are milliliters per centimeter H2O.
bThe units for resistance are centimeter H2O/L/s.
cSF ratio signifies the oxygen saturation to the fraction of inspired oxygen ratio.
Lynch reported a retrospective case series of 13 neonates with
non-oliguric AKI and described an improvement in renal func-
tion indices with aminophylline (9). However, in that publication,
urine outputs were not reported, and many of the subjects were
receiving concomitant caffeine, which shares similar properties
of aminophylline (9). In a relatively recent retrospective study of
nine children with AKI, aminophylline use resulted in improved
urine flow rates, stable creatinine concentrations, and a reduced
requirement for dialysis (10). Although each of these studies sup-
ports a beneficial effect of aminophylline in renal injury, all have
significant limitations. The findings of this current report suggest
in a prospective manner, with a relatively large sample size, that
this therapeutic intervention can increase urine output while not
increasing BUN or creatinine concentrations suggesting improved
renal perfusion. The results also suggest that this response may be
age dependent; however, given the small subgroup sample sizes,
this finding can, at best, be used solely to inform future study
design.
The purported renal benefits of aminophylline have been
attributed to two mechanisms: adenosine receptor blockade at
low dosage and type IV phosphodiesterase inhibition at high
levels. Adenosine is the putative mediator of tubuloglomerular
feedback (22). When the tubule is exposed to increased solute,
energy depletion occurs, and adenosine is released. The released
adenosine triggers pre-glomerular vasoconstriction thereby limit-
ing solute flow and, in theory, restoring energy balance. In addition
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Table 5 | Characteristics of patients with documented side effects.
Diagnoses Side effect Day Associated clinical condition
S/P cardiopulmonary arrest Increased NG output 3 Cardiomyopathy
Hypoxic ischemic encephalopathy
Pneumonia PVCs/bradycardia 2 Pulmonary hypertension
Obstructive sleep apnea Sinus arrhythmia PVCs resolved with potassium and
magnesium therapy
Severe septic shock
AML
SVT/VT
Junctional tachycardia
3 Hypotensive, febrile, oliguric,
acidotic; died 3 days later
ASD repaired 11 years ago
Severe septic shock
Necrotizing enterocolitis
SVT 3 SVT occurred following albuterol
and aminophylline dose; resolved
with vagal maneuver
Pneumonia Sinus tachycardia 2 Heart rate in the 190–210
SMA type 1
RSV bronchiolitis
TOF (previously repaired)
PACs 2 PACs resolved with potassium
RSV bronchiolitis Agitation 7
NG, nasogastric; PVCs, premature ventricular contractions; SVT, supraventricular tachycardia; VT, ventricular tachycardia; AML, acute myelocytic leukemia; ASD,
atrioventricular septal defect; SMA, spinal muscular atrophy; RSV, respiratory syncytial; PACs, premature atrial contractions; TOF, Tetralogy of Fallot.
to adenosine receptor blockade, aminophylline-induced phospho-
diesterase inhibition may prevent the hydrolysis of cAMP, which is
important in the mediation of renal blood flow as it promotes renal
vasodilatation (23). Both of these mechanisms likely contribute to
the improved renal blood flow attributed to aminophylline.
In addition to its effect on the kidneys, significant reductions
in cytokines IL-6, IL-10, and to a lesser degree IL-8, were detected
following 24 h of aminophylline therapy. Aminophylline has been
found to influence the immune response in other reports. Studies
have demonstrated that aminophylline can suppress the release
of eosinophil cationic protein (13), induce apoptosis of activated
eosinophils (13), inhibit eosinophil chemotaxis in response to
multiple stimuli (14), and suppress mitogen-induced secretion
of pro-inflammatory cytokines from human peripheral blood
lymphocytes (15). In addition, Luo demonstrated significantly
lower concentrations of IL-8 and TNF-alpha, and significantly
higher concentrations of IL-10 in adult patients receiving amino-
phylline during cardiopulmonary bypass for valve replacement
(24). Although their results differ from ours, they observed
a dramatic surge in cytokines after baseline with the use of
cardiopulmonary bypass confounding any comparison.
The mechanism by which aminophylline suppresses inflam-
mation is not entirely established. It has been demonstrated
that its anti-inflammatory effect can occur at doses significantly
smaller than typical bronchodilator doses (i.e., concentrations
lower than those needed to produce phosphodiesterase inhibi-
tion) (25). Theophylline concentrations on the order of those
reported in this study have been found to suppress endotoxin-
induced TNF-alpha production by monocytes in vivo (26). Thus,
it has been postulated that the anti-inflammatory effects may
be due to mechanisms other than phosphodiesterase inhibi-
tion. Adenosine receptor antagonism (27), an increase in his-
tone deacetylase activity (28), and/or enhanced messenger RNA
and protein levels of peroxisomal proliferator-activated receptor-
gamma (PPAR-gamma) expression (29) have all been reported as
potential explanations.
Additionally, aminophylline exerts a number of beneficial
effects on pulmonary function via phosphodiesterase inhibi-
tion, adenosine receptor antagonism, and increased catecholamine
release. In addition to bronchodilation, it has also been found
to decrease mucosal edema (30) and excessive secretions (31),
enhance respiratory muscle contractility (32) and stimulate the
medullary respiratory center (33). In this study, aminophylline was
found to have little effect on airway resistance or respiratory com-
pliance. The lack of effect on airway resistance could seemingly
be explained by the small and heterogeneous sample. However,
other physiologic explanations exist. For example, a large num-
ber of patients in the trial had no evidence of increased airway
resistance. If bronchospasm is absent, the effects of aminophylline
on air flow and respiratory mechanics may be minimal (34).
In addition, aminophylline-induced-bronchodilation is propor-
tional to the log of the plasma theophylline concentration over
a range of 5–25µg/mL (35). It is plausible that the relatively
low levels of theophylline attained in this trial were insufficient
to induce significant bronchodilation. Moreover, the ability of
aminophylline to produce bronchodilation is most likely sec-
ondary to phosphodiesterase inhibition and varies from patient to
patient (36). In therapeutic doses, aminophylline can only inhibit
between 5 and 20% of total phosphodiesterase activity in human
lungs (37).
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Any conclusions drawn from this report regarding amino-
phylline use must be tempered by the obvious study limitations,
and the potential for significant side effects. First, the uncontrolled
design of this study confounds any definitive interpretation of the
results. It is impossible to determine if the improvement in urine
output and the reductions reported in cytokine concentrations
were truly the result of aminophylline therapy or the natural course
of disease. Although the study patients consisted of a diverse group
of diagnoses at variable stages of their disease course, a true effect
of aminophylline on urine output and inflammation can only be
discerned with the use of an appropriate control group. Second,
the study is limited by the small sample size and the diverse patient
population. Although the small sample size clearly limits the analy-
sis of the study data and its extrapolation, it is important to note
that this study population is larger than any of the previous reports
assessing the diuretic and anti-inflammatory properties of amino-
phylline in critically ill infants and children. Moreover, an analysis
by age group was conducted to minimize some of the heterogene-
ity associated with the large age range of study patients. Finally, the
apparent benefits of aminophylline therapy for this patient popu-
lation must be balanced against the potential for adverse sequelae
associated with its use. Although pulmonary, renal and inflam-
matory effects were assessed for only 24 h, side effects beyond the
24-h study period were reported for completeness.
In light of these clear and acknowledged weaknesses and con-
cerns, the results of this study cannot be considered definitive
and the use of aminophylline cannot be routinely recommended
for the purposes of augmenting urine output and/or decreasing
inflammation in critically ill children. Current national guidelines
only suggest that a single dose of theophylline may be adminis-
tered to neonates with severe perinatal asphyxia at risk for AKI
(38). The findings of this study suggest that aminophylline may
be of benefit in other populations. A recent publication suggests
that it may improve renal function in children with AKI and con-
genital or acquired cardiac disease admitted to the cardiovascular
intensive care unit (39). Given the surge of publications implicat-
ing positive fluid balance with worse outcomes in adults (40) and
children (41, 42), and the established deleterious consequences of
uncontrolled inflammation in the critically ill, the use of amino-
phylline has the potential to be of much benefit for these children.
The results of this trial should serve to stimulate and inform
well designed, randomized, controlled trials that may provide the
needed insight to direct the appropriate use of aminophylline in
critically ill children balancing potential benefit against the risk of
toxicity.
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